Cargando…

Prognostic Value of Serial Galectin‐3 Measurements in Patients With Acute Heart Failure

BACKGROUND: Several clinical studies have evaluated the association between galectin‐3 levels and outcome in patients with heart failure (HF). However, little is known about the predictive value of repeated galectin‐3 measurements. This study evaluates the prognostic value of repeated time‐dependent...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Vark, Laura C., Lesman‐Leegte, Ivonne, Baart, Sara J., Postmus, Douwe, Pinto, Yigal M., de Boer, Rudolf A., Asselbergs, Folkert W., Wajon, Elly M. C. J., Orsel, Joke G., Boersma, Eric, Hillege, Hans L., Akkerhuis, K. Martijn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778986/ https://www.ncbi.nlm.nih.gov/pubmed/29187387 http://dx.doi.org/10.1161/JAHA.116.003700

Ejemplares similares

Multimarker Analysis of Serially Measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, Creatinine, and Prognosis in Acute Heart Failure
por: Gürgöze, Muhammed T., et al.
Publicado: (2022)

A heart failure phenotype stratified model for predicting 1-year mortality in patients admitted with acute heart failure: results from an individual participant data meta-analysis of four prospective European cohorts
por: Chen, Yuntao, et al.
Publicado: (2021)

Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients
por: van Vark, Laura C., et al.
Publicado: (2012)

A simulated maximum likelihood procedure for analyzing imprecise trade‐off thresholds between the benefits and harms of medicines
por: Postmus, Douwe, et al.
Publicado: (2022)

Machine learning–based biomarker profile derived from 4210 serially measured proteins predicts clinical outcome of patients with heart failure
por: de Bakker, Marie, et al.
Publicado: (2023)

Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration
por: Cao, Qi, et al.
Publicado: (2018)

Sex-based differences in cardiovascular proteomic profiles and their associations with adverse outcomes in patients with chronic heart failure
por: de Bakker, Marie, et al.
Publicado: (2023)

Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research
por: van Asselt, Thea, et al.
Publicado: (2017)

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
por: de Boer, Rudolf A, et al.
Publicado: (2011)

ST2 and Galectin-3: Ready for Prime Time?
por: Meijers, Wouter C., et al.
Publicado: (2016)

Galectin-3 in Cardiac Remodeling and Heart Failure
por: de Boer, Rudolf A., et al.
Publicado: (2010)

Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study
por: Roldan Munoz, Sonia, et al.
Publicado: (2021)

What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study
por: Roldan Munoz, Sonia, et al.
Publicado: (2023)

Patients with heart failure with and without a history of stroke in the Netherlands: a secondary analysis of psychosocial, behavioural and clinical outcomes up to three years from the COACH trial
por: Ski, Chantal F, et al.
Publicado: (2019)

Erratum to: Galectin-3 in Cardiac Remodeling and Heart Failure
por: de Boer, Rudolf A., et al.
Publicado: (2012)

Renal tubular damage and worsening renal function in chronic heart failure: Clinical determinants and relation to prognosis (Bio‐SHiFT study)
por: Brankovic, Milos, et al.
Publicado: (2020)

Family caregivers’ perspectives on their interaction and relationship with people living with dementia in a nursing home: a qualitative study
por: van Corven, Charlotte T. M., et al.
Publicado: (2022)

Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model
por: Oemrawsingh, Rohit M., et al.
Publicado: (2016)

Details on high frequency blood collection, data analysis, available material and patient characteristics in BIOMArCS
por: Boersma, Eric, et al.
Publicado: (2019)

Serially measured high-sensitivity cardiac troponin T, N-terminal-pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and growth differentiation factor 15 for risk assessment after acute coronary syndrome: the BIOMArCS cohort
por: Gürgöze, Muhammed T, et al.
Publicado: (2023)

Bilateral Pallidotomy for Dystonia: A Systematic Review
por: Centen, Liesanne M., et al.
Publicado: (2020)

Dynamic personalized risk prediction in chronic heart failure patients: a longitudinal, clinical investigation of 92 biomarkers (Bio-SHiFT study)
por: Klimczak-Tomaniak, Dominika, et al.
Publicado: (2022)

CXCL$_{10}$ Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study
por: Altara, Raffaele, et al.
Publicado: (2016)

HFrEF subphenotypes based on 4210 repeatedly measured circulating proteins are driven by different biological mechanisms
por: Petersen, Teun B., et al.
Publicado: (2023)

Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update
por: Suthahar, Navin, et al.
Publicado: (2018)

Prognostic Value of Serial N‐Terminal Pro‐B‐Type Natriuretic Peptide Measurements in Adults With Congenital Heart Disease
por: Baggen, Vivan J. M., et al.
Publicado: (2018)

The Association of the Metabolic Syndrome with PAI-1 and t-PA Levels
por: Coffey, Christopher S., et al.
Publicado: (2011)

Circulating Biomarkers of Cell Adhesion Predict Clinical Outcome in Patients with Chronic Heart Failure
por: Bouwens, Elke, et al.
Publicado: (2020)

Serial transplantation unmasks galectin-9 contribution to tumor immune escape in the MB49 murine model
por: Baloche, Valentin, et al.
Publicado: (2021)

From Individual to Population Preferences: Comparison of Discrete Choice and Dirichlet Models for Treatment Benefit-Risk Tradeoffs
por: Tervonen, Tommi, et al.
Publicado: (2019)

Individual Trade‐Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma
por: Postmus, Douwe, et al.
Publicado: (2017)

Cardiovascular Risk Associated with Interactions among Polymorphisms in Genes from the Renin-Angiotensin, Bradykinin, and Fibrinolytic Systems
por: Bentley, John P., et al.
Publicado: (2010)

Using Multicriteria Decision Analysis to Support Research Priority Setting in Biomedical Translational Research Projects
por: de Graaf, Gimon, et al.
Publicado: (2015)

Temporal Evolution of Serum Concentrations of High‐Sensitivity Cardiac Troponin During 1 Year After Acute Coronary Syndrome Admission
por: van den Berg, Victor J., et al.
Publicado: (2020)

Joint models for longitudinal and time‐to‐event data in a case‐cohort design
por: Baart, Sara J., et al.
Publicado: (2019)

Nutrient levels and trade-offs control diversity in a serial dilution ecosystem
por: Erez, Amir, et al.
Publicado: (2020)

Galectin-3 and galectin-3 binding protein in rheumatoid arthritis
por: Ohshima, S, et al.
Publicado: (2003)

A Genome-Wide Association Study of Circulating Galectin-3
por: de Boer, Rudolf A., et al.
Publicado: (2012)

The early economic evaluation of novel biomarkers to accelerate their translation into clinical applications
por: de Graaf, Gimon, et al.
Publicado: (2018)

Placental Expression Patterns of Galectin-1, Galectin-2, Galectin-3 and Galectin-13 in Cases of Intrauterine Growth Restriction (IUGR)
por: Hutter, Stefan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_loai2o7de73j7vupu8l06vbv1s